結核診断の市場規模、シェア、予測、動向分析：検査タイプ別、エンドユーザー別、感染ステージ別-2031年までの世界の予測

結核診断市場は2031年までに35億6,000万米ドルに達し、2024年から2031年までのCAGRは5.0%に達すると予測されます。徹底的な2次調査と1次調査、市場シナリオの詳細分析に続き、主要な市場促進要因・阻害要因・課題・機会・動向について論じています。

この市場の成長を牽引しているのは、中低所得国における結核の有病率の上昇、薬剤耐性株の出現、結核の診断と治療に対する好意的な取り組みです。さらに、結核に対する認識を高めるための政府や組織による取り組みが、結核診断市場で事業を展開するプレーヤーに成長機会をもたらすと期待されています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場洞察

• 概要
• 市場成長の要因
  • 市場力学
    • 促進要因
      • LMICsにおける結核の有病率の上昇
      • 薬剤耐性株の出現
      • 結核の診断と治療に対する積極的な取り組み
    • 抑制要因
      • 結核検査に関連する問題
      • 偽陽性
      • 免疫反応の遅れによる検査結果の遅延
      • 検査の感度不良
    • 機会
      • 結核に関する認識を高めるための政府や組織による取り組み
    • 課題
      • 結核患者に対するスティグマ
• 動向
  • ポイントオブケア検査の出現
  • 結核のバイオマーカー調査
• 規制分析
• ポーターのファイブフォース分析
• 製品パイプライン分析
• 資金調達と投資分析

第5章 結核診断市場：検査タイプ別評価

• 検査概要
• 皮膚検査/マントゥ検査
• インターフェロンγ放出アッセイ
• X線検査
  • 胸部X線
  • コンピューター断層撮影
• 分子検査
  • 迅速診断検査
  • 全ゲノム配列決定
  • 核酸増幅検査
  • その他の分子検査
• 喀痰塗抹顕微鏡検査
• 培養と薬剤耐性
• その他の検査タイプ

第6章 結核診断市場：感染ステージ別評価

• 概要
• 活動性
• 潜伏

第7章 結核診断市場：エンドユーザー別評価

• 概要
• 診断ラボ
• 病院・診療所
• 学術・研究機関
• その他のエンドユーザー

第8章 結核診断市場：地域別評価

• 概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • インドネシア
  • タイ
  • フィリピン
  • 韓国
  • シンガポール
  • オーストラリア
  • その他アジア太平洋地域
• ラテンアメリカ
• 中東
• アフリカ
  • 南アフリカ
  • ナイジェリア
  • ケニア
  • その他のアフリカ

第9章 競合分析

• 概要
• 主要成長戦略
• 競合ベンチマーキング
• 競合ダッシュボード
  • 業界リーダー
  • 市場差別化要因
  • 先行企業
  • 新興企業
• 主要企業別市場シェア分析/市場ランキング（2023年）

第10章 企業プロファイル（事業概要、財務概要、製品ポートフォリオ、戦略的展開）

• F. Hoffmann-La Roche Ltd.
• Becton, Dickinson and Company
• Abbott Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• QIAGEN GmbH
• Hologic, Inc.
• bioMerieux SA（France）
• Danaher Corporation
• Oxford Immunotec Ltd.（U.K.）
• Hain Lifescience GmbH
• Creative Diagnostics

（注：上位5社のSWOT分析を掲載予定）

第11章 付録

LIST OF TABLES

• Table 1 Global Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 2 Global Tuberculosis Skin Test Market, by Country/Region, 2022-2031 (USD Million)
• Table 3 Global Tuberculosis Interferon Gamma Release Assay Market, by Country/Region, 2022-2031 (USD Million)
• Table 4 Global Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 5 Global Tuberculosis Chest X-ray Market, by Country/Region, 2022-2031 (USD Million)
• Table 6 Global Tuberculosis Computed Tomography Market, by Country/Region, 2022-2031 (USD Million)
• Table 7 Global Molecular Tests Market for Tuberculosis, by Country/Region, 2022-2031 (USD Million)
• Table 8 Global Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 9 Global Rapid Diagnostic Tests Market for Tuberculosis, by Country/Region, 2022-2031 (USD Million)
• Table 10 Global Whole-genome Sequencing Market for Tuberculosis, by Country/Region, 2022-2031 (USD Million)
• Table 11 Global Nucleic Acid Amplification Test Market for Tuberculosis, by Country/Region, 2022-2031 (USD Million)
• Table 12 Global Other Molecular Tests Market for Tuberculosis, by Country/Region, 2022-2031 (USD Million)
• Table 13 Global Sputum Smear Microscopy Market for Tuberculosis, by Country/Region, 2022-2031 (USD Million)
• Table 14 Global Culture & Drug Resistance Market for Tuberculosis, by Country/Region, 2022-2031 (USD Million)
• Table 15 Global Other Test Types Market for Tuberculosis, by Country/Region, 2022-2031 (USD Million)
• Table 16 Global Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 17 Global Active Tuberculosis Diagnostics Market, by Country/Region, 2022-2031 (USD Million)
• Table 18 Global Latent Tuberculosis Diagnostics Market, by Country/Region, 2022-2031 (USD Million)
• Table 19 Global Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 20 Global Tuberculosis Diagnostics Market for Diagnostic Laboratories, by Country/Region, 2022-2031 (USD Million)
• Table 21 Global Tuberculosis Diagnostics Market for Hospitals & Clinics, by Country/Region, 2022-2031 (USD Million)
• Table 22 Global Tuberculosis Diagnostics Market for Academic & Research Institutes, by Country/Region, 2022-2031 (USD Million)
• Table 23 Global Contract Manufacturing Market for Other End Users, by Country/Region, 2022-2031 (USD Million)
• Table 24 Global Tuberculosis Diagnostics Market, by Country/Region, 2022-2031 (USD Million)
• Table 25 North America: Tuberculosis Diagnostics Market, by Country, 2022-2031 (USD Million)
• Table 26 North America: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 27 North America: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 28 North America: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 29 North America: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 30 North America: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 31 U.S.: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 32 U.S.: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 33 U.S.: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 34 U.S.: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 35 U.S.: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 36 Canada: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 37 Canada: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 38 Canada: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 39 Canada: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 40 Canada: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 41 Europe: Tuberculosis Diagnostics Market, by Country/Region, 2022-2031 (USD Million)
• Table 42 Europe: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 43 Europe: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 44 Europe: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 45 Europe: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 46 Europe: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 47 Germany: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 48 Germany: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 49 Germany: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 50 Germany: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 51 Germany: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 52 France: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 53 France: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 54 France: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 55 France: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 56 France: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 57 U.K.: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 58 U.K.: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 59 U.K.: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 60 U.K.: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 61 U.K.: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 62 Italy: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 63 Italy: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 64 Italy: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 65 Italy: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 66 Italy: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 67 Spain: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 68 Spain: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 69 Spain: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 70 Spain: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 71 Spain: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 72 Rest of Europe: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 73 Rest of Europe: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 74 Rest of Europe: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 75 Rest of Europe: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 76 Rest of Europe: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 77 Asia-Pacific: Tuberculosis Diagnostics Market, by Country/Region, 2022-2031 (USD Million)
• Table 78 Asia-Pacific: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 79 Asia-Pacific: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 80 Asia-Pacific: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 81 Asia-Pacific: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 82 Asia-Pacific: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 83 China: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 84 China: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 85 China: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 86 China: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 87 China: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 88 India: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 89 India: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 90 India: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 91 India: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 92 India: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 93 Japan: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 94 Japan: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 95 Japan: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 96 Japan: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 97 Japan: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 98 Indonesia: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 99 Indonesia: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 100 Indonesia: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 101 Indonesia: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 102 Indonesia: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 103 Thailand: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 104 Thailand: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 105 Thailand: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 106 Thailand: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 107 Thailand: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 108 Philippines: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 109 Philippines: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 110 Philippines: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 111 Philippines: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 112 Philippines: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 113 South Korea: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 114 South Korea: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 115 South Korea: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 116 South Korea: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 117 South Korea: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 118 Singapore: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 119 Singapore: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 120 Singapore: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 121 Singapore: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 122 Singapore: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 123 Australia: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 124 Australia: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 125 Australia: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 126 Australia: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 127 Australia: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 128 Rest of Asia-Pacific: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 129 Rest of Asia-Pacific: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 130 Rest of Asia-Pacific: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 131 Rest of Asia-Pacific: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 132 Rest of Asia-Pacific: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 133 Latin America: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 134 Latin America: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 135 Latin America: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 136 Latin America: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 137 Latin America: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 138 Middle East: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 139 Middle East: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 140 Middle East: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 141 Middle East: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 142 Middle East: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 143 Africa: Tuberculosis Diagnostics Market, by Country/Region, 2022-2031 (USD Million)
• Table 144 Africa: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 145 Africa: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 146 Africa: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 147 Africa: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 148 Africa: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 149 South Africa: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 150 South Africa: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 151 South Africa: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 152 South Africa: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 153 South Africa: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 154 Nigeria: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 155 Nigeria: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 156 Nigeria: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 157 Nigeria: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 158 Nigeria: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 159 Kenya: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 160 Kenya: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 161 Kenya: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 162 Kenya: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 163 Kenya: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 164 Rest of Africa: Tuberculosis Diagnostics Market, by Test Type, 2022-2031 (USD Million)
• Table 165 Rest of Africa: Tuberculosis Radiographic Tests Market, by Type, 2022-2031 (USD Million)
• Table 166 Rest of Africa: Molecular Tests Market for Tuberculosis, by Type, 2022-2031 (USD Million)
• Table 167 Rest of Africa: Tuberculosis Diagnostics Market, by Infection Stage, 2022-2031 (USD Million)
• Table 168 Rest of Africa: Tuberculosis Diagnostics Market, by End User, 2022-2031 (USD Million)
• Table 169 Recent Developments, by Company, 2021-2023

LIST OF FIGURES

• Figure 1 Research Process
• Figure 2 Secondary Sources Referenced for This Study
• Figure 3 Primary Research Techniques
• Figure 4 Key Executives Interviewed
• Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
• Figure 6 Market Sizing and Growth Forecast Approach
• Figure 7 Global Tuberculosis Diagnostics Market, by Test Type, 2024 Vs.2031 (USD Million)
• Figure 8 Global Tuberculosis Diagnostics Market, by Infection Stage, 2024 Vs.2031 (USD Million)
• Figure 9 Global Tuberculosis Diagnostics Market, by End User, 2024 Vs.2031 (USD Million)
• Figure 10 Global Tuberculosis Diagnostics Market, by Geography
• Figure 11 Impact Analysis of Market Dynamics
• Figure 12 Global Tuberculosis Diagnostics Market, by Test Type, 2024 Vs.2031 (USD Million)
• Figure 13 Global Tuberculosis Diagnostics Market, by Infection Stage, 2024 Vs.2031 (USD Million)
• Figure 14 Global Tuberculosis Diagnostics Market, by End User, 2024 Vs.2031 (USD Million)
• Figure 15 North America: Tuberculosis Diagnostics Market Snapshot
• Figure 16 Europe: Tuberculosis Diagnostics Market Snapshot
• Figure 17 Asia-Pacific: Tuberculosis Diagnostics Market Snapshot
• Figure 18 Africa: Tuberculosis Diagnostics Market Snapshot
• Figure 19 Key Growth Strategies Adopted by Leading Players (2021-2024)
• Figure 20 Tuberculosis Diagnostics Market: Competitive Benchmarking, by Application
• Figure 21 Tuberculosis Diagnostics Market: Competitive Benchmarking, by Region
• Figure 22 Competitive Dashboard Tuberculosis Diagnostics Market
• Figure 23 Global Tuberculosis Diagnostics Market Share/Market Ranking Analysis, by Key Players, 2023
• Figure 24 F. Hoffmann-La Roche Ltd..: Financial Overview (2023)
• Figure 25 Becton, Dickinson and Company.: Financial Overview (2023)
• Figure 26 Abbott Laboratories, Inc.: Financial Overview (2023)
• Figure 27 Thermo Fisher Scientific, Inc.: Financial Overview (2023)
• Figure 28 QIAGEN GmbH: Financial Overview (2023)
• Figure 29 Hologic, Inc.: Financial Overview (2023)
• Figure 30 bioMerieux SA: Financial Overview (2023)

Tuberculosis Diagnostics Market Size, Share, Forecast, & Trends Analysis by Test Type (Mantoux, IGRA, Radiography [X-ray, CT] Molecular [NAAT, WGS, Rapid] Culture, Sputum Smear), End User (Hospital, Diagnostic Lab), Infection Stage - Global Forecast to 2031

The tuberculosis diagnostics market is expected to reach $3.56 Billion by 2031, at a CAGR of 5.0% from 2024 to 2031. Following thorough secondary and primary research and in-depth analysis of the market scenario, the report discusses key industry drivers, restraints, challenges, opportunities, and trends

The growth of this market is driven by the rising prevalence of tuberculosis (TB) in low-and middle-income countries, the emergence of drug-resistant strains, and favorable initiatives for TB diagnosis and treatment. Moreover, initiatives by governments and organizations to raise awareness about tuberculosis are expected to generate growth opportunities for the players operating in the tuberculosis diagnostics market.

Based on test type, the market is segmented into skin test/Mantoux, radiographic tests, molecular tests, sputum smear microscopy, culture & drug resistance tests, and other test types. The molecular tests segment is projected to register the highest growth rate of 5.8% during the forecast period of 2024-2031. This segment's growth is driven by the high efficiency & accuracy of molecular tests, technological advancements in molecular diagnostic technology, increasing availability of molecular tests for TB, and initiatives by market players to introduce rapid molecular diagnostic tests for TB & drug resistance. Moreover, new guidelines by public organizations such as the WHO regarding molecular TB tests further drive the segment's growth. For instance, in March 2024, the WHO published recommendations on the use of a new class of diagnostic technologies: targeted next-generation sequencing (NGS) tests for the diagnosis of drug-resistant tuberculosis (TB).

Based on infection stage, the tuberculosis diagnostics market is segmented into active and latent. The active segment is expected to register the highest CAGR during the forecast period of 2024-2031. This growth can be attributed to the increasing prevalence of tuberculosis in low- and middle-income countries, aims and goals set by governments and public organizations to manage the TB burden, and growing instances of TB outbreaks.

Based on end user, the tuberculosis diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, academic & research institutes, and other end users. The diagnostic laboratories segment is expected to register the highest CAGR during the forecast period. This growth is driven by the increasing adoption of advanced technologies for TB diagnosis, including next-generation sequencing. Furthermore, diagnostic laboratories are more capable of investing in such technologies compared to clinics and small to medium-sized hospitals. Additionally, government and organizational initiatives aimed at raising awareness about tuberculosis further contribute to the segment's growth.

An in-depth analysis of the geographical scenario of the tuberculosis diagnostics market provides detailed qualitative and quantitative insights into five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of 34.1% of the global tuberculosis diagnostics market, followed by Europe and Asia-Pacific.

However, the market in Asia-Pacific is projected to register the highest CAGR during the forecast period. Within Asia-Pacific, India and China are expected to present significant growth opportunities for players in the tuberculosis diagnostic market due to their large populations, high incidence of tuberculosis cases, and rising investments in healthcare. Additionally, the strong economic growth in both countries enables substantial investments in healthcare infrastructure and advancing tuberculosis testing technologies.

Key companies operating in the tuberculosis diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (U.S.), Abbott Laboratories, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), QIAGEN GmbH (Germany), Hologic, Inc. (U.S.), bioMerieux SA (France), Danaher Corporation (U.S.), Oxford Immunotec Ltd. (U.K.), Hain Lifescience GmbH (Germany), Creative Diagnostics (U.S.).

Scope of the Report:

Tuberculosis Diagnostics Market Assessment-by Test Type

• Skin Test/Mantoux
• Interferon Gamma Release Assay
• Radiographic Tests
  • Chest X-rays
  • Computed Tomography
• Molecular Tests
  • Rapid Diagnostic Tests
  • Whole-genome Sequencing
  • Nucleic Acid Amplification Test
  • Other Molecular Tests (Sangers Sequencing, Pyrosequencing)
• Sputum Smear Microscopy
• Culture & Drug resistance
• Other Test Types

(Note: Other Test Types include Urine Test, Breath Test, Cytokine Detection Assay, Cerebrospinal Fluid Test)

Tuberculosis Diagnostics Market Assessment-by Infection Stage

• Active
• Latent

Tuberculosis Diagnostics Market Assessment-by End User

• Diagnostic Laboratories
• Hospitals & Clinics
• Other End Users

(Note: Other End Users include government, private organizations, and NGOs)

Tuberculosis Diagnostics Market Assessment-by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia-Pacific (APAC)
  • Japan
  • China
  • India
  • Indonesia
  • Thailand
  • Philippines
  • Singapore
  • South Korea
  • Australia
  • Rest of Asia-Pacific (RoAPAC)
• Latin America
• Middle East
• Africa
  • South Africa
  • Kenya
  • Nigeria
  • Rest of Africa

TABLE OF CONTENTS

1. Overview

• 1.1. Market Definition and Scope
• 1.2. Market Ecosystem
• 1.3. Currency & Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process of Data Collection and Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of The Industry
• 2.3. Market Sizing and Forecast
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
  • 2.3.3. Market Share Analysis
• 2.4. Assumptions For the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Factors Affecting Market Growth
  • 4.2.1. Market Dynamics
    • 4.2.1.1. Drivers
      • 4.2.1.1.1. Rising Prevalence of Tuberculosis in LMICs
      • 4.2.1.1.2. Emergence of Drug Resistant Strains
      • 4.2.1.1.3. Favorable Initiatives for TB Diagnosis and Treatment
    • 4.2.1.2. Restraints
      • 4.2.1.2.1. Problems Associated with TB Testing
      • 4.2.1.2.1.1. False Positives
      • 4.2.1.2.1.2. Delays in Test Results Due to Delay in Immune Reaction
      • 4.2.1.2.1.3. Poor Sensitivity of Tests
    • 4.2.1.3. Opportunities
      • 4.2.1.3.1. Initiatives by Governments and Organizations to Raise Awareness Regarding Tuberculosis
    • 4.2.1.4. Challenges
      • 4.2.1.4.1. Stigma Associated Regarding TB Patients
• 4.3. Trends
  • 4.3.1. Emergence of Point-of-Care Testing
  • 4.3.2. Biomarker Research for TB
• 4.4. Regulatory Analysis
• 4.5. Porters Five Forces Analysis
• 4.6. Product Pipeline Analysis
• 4.7. Fundings & Investment Analysis

5. Tuberculosis Diagnostics Market Assessment-by Test Type

• 5.1. Overview
• 5.2. Skin Test/Mantoux
• 5.3. Interferon Gamma Release Assay
• 5.4. Radiographic Tests
  • 5.4.1. Chest X-rays
  • 5.4.2. Computed Tomography
• 5.5. Molecular Tests
  • 5.5.1. Rapid Diagnostic Tests
  • 5.5.2. Whole Genome Sequencing
  • 5.5.3. Nucleic Acid Amplification Test
  • 5.5.4. Other Molecular Tests
• 5.6. Sputum Smear Microscopy
• 5.7. Culture & Drug Resistance
• 5.8. Other Test Types

6. Tuberculosis Diagnostics Market Assessment-by Infection Stage

• 6.1. Overview
• 6.2. Active
• 6.3. Latent

7. Tuberculosis Diagnostics Market Assessment-by End User

• 7.1. Overview
• 7.2. Diagnostic Laboratories
• 7.3. Hospitals & Clinics
• 7.4. Academic & Research Institutes
• 7.5. Other End Users

8. Tuberculosis Diagnostics Market Assessment-by Geography

• 8.1. Overview
• 8.2. North America
  • 8.2.1. U.S.
  • 8.2.2. Canada
• 8.3. Europe
  • 8.3.1. Germany
  • 8.3.2. France
  • 8.3.3. U.K.
  • 8.3.4. Italy
  • 8.3.5. Spain
  • 8.3.6. Rest of Europe
• 8.4. Asia-Pacific
  • 8.4.1. China
  • 8.4.2. India
  • 8.4.3. Japan
  • 8.4.4. Indonesia
  • 8.4.5. Thailand
  • 8.4.6. Philippines
  • 8.4.7. South Korea
  • 8.4.8. Singapore
  • 8.4.9. Australia
  • 8.4.10. Rest of Asia-Pacific
• 8.5. Latin America
• 8.6. Middle East
• 8.7. Africa
  • 8.7.1. South Africa
  • 8.7.2. Nigeria
  • 8.7.3. Kenya
  • 8.7.4. Rest of Africa

9. Competition Analysis

• 9.1. Overview
• 9.2. Key Growth Strategies
• 9.3. Competitive Benchmarking
• 9.4. Competitive Dashboard
  • 9.4.1. Industry Leaders
  • 9.4.2. Market Differentiators
  • 9.4.3. Vanguards
  • 9.4.4. Emerging Companies
• 9.5. Market Share Analysis/Market Ranking, by Key Players (2023)

10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)

• 10.1. F. Hoffmann-La Roche Ltd.
• 10.2. Becton, Dickinson and Company
• 10.3. Abbott Laboratories, Inc.
• 10.4. Thermo Fisher Scientific, Inc.
• 10.5. QIAGEN GmbH
• 10.6. Hologic, Inc.
• 10.7. bioMerieux SA (France)
• 10.8. Danaher Corporation
• 10.9 Oxford Immunotec Ltd. (U.K.)
• 10.10. Hain Lifescience GmbH
• 10.11. Creative Diagnostics

(Note: SWOT analysis of the top 5 companies will be provided)

11. Appendix

• 11.1. Available Customization
• 11.2. Related Reports